Dergiler / European Journal of Breast Health / 2019 / Cilt: 15 - Sayı: 1

Adiponectin: A Predictor for Breast Cancer Survival?

Sayfa
13–17
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In order for adiponectin to be used as a practical clinical marker for breast cancer, large databasestudies are should be conducted.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Breast cancers in women with low serum adiponectin levels have been reported to show phenotypes that are more aggressive.
📊
Temel Bulgular & Veri:In 2008,we investigated the relationship between serum adiponectin levels and breast cancer in our case-controlled study involving 83 patients, in whichserum adiponectin levels were measured preoperatively.
💡
Sonuç & Katkı:In order for adiponectin to be used as a practical clinical marker for breast cancer, large databasestudies are should be conducted.
🔬Tür:Araştırma Makalesi
📍Kapsam:2008 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Breast cancers in women with low serum adiponectin levels have been reported to show phenotypes that are more aggressive. In 2008,we investigated the relationship between serum adiponectin levels and breast cancer in our case-controlled study involving 83 patients, in whichserum adiponectin levels were measured preoperatively. In this study, we aimed to investigate the relationship between serum adiponectin levels andbreast cancer-specific survival among these 83 patients.Materials and Methods: All 83 patients with stage I-III breast cancer, whose adiponectin levels were measured preoperatively in 2008 wereenrolled in this study. The patients had no history of medications influencing insulin resistance prior to collecting the blood samples. Serum adiponectinconcentrations were measured after overnight fasting (≥12 hours) by drawing a venous blood sample of 30 mL from the arm. ELISA (B-BridgeHuman Adiponectin ELISA kit) was used for testing.Results: The mean adiponectin level was found to be 15,300 ng/mL. When the adiponectin levels of the patients were analyzed according to thestage of the disease, adiponectin levels tended to be significantly lower as the stage increased. The stage of the disease was an important determinantfor both Diseas Free Survival (DFS) (p=0.003) and Overall Survival (OS) (p=0.005). A significant relationship between adiponectin levels and OSwas also observed (p=0.025), and levels of adiponectin above the mean value of 15,300 ng/mL were associated with improved DFS (p=0.001).Conclusion: Preoperative adiponectin levels may be useful to predict survival rates in breast cancer or may be used as a marker/predictor for definingpatients who require more aggressive treatment. In order for adiponectin to be used as a practical clinical marker for breast cancer, large databasestudies are should be conducted.

🔖

Bu Makaleye Atıf Yap

DOĞAN, L., GÜVEN, H. E., GÜLÇELİK, N. E., GÜLÇELİK, M. A. (2022). Adiponectin: A Predictor for Breast Cancer Survival?. European Journal of Breast Health, Cilt: 15 - Sayı: 1, 13–17. https://ajindex.com/articles/510815

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Romero-Figueroa Mdel S, Gardu-o-GarcíaJde J, Duarte-Mote J, Matute- González G, Gómez-Villanueva A, De la Cruz-Vargas J. Insulin and leptin levels in obese patients with and without breast cancer. Clin Breast Cancer 2013
  2. (PMID: 24084031) [CrossRef] 2. Wauters M, Considine RV, Yudkin JS, Peiffer F, De Leeuw I, Van Gaal LF. Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res 2003
  3. (PMID: 12734788) [CrossRef] 3. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol and Metabol 2005
  4. (PMID: 16311216) [CrossRef] 4. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007
  5. (PMID: 18265479) [CrossRef] 5. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006
  6. (PMID: 16570048) [CrossRef] 6. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003
  7. (PMID: 14654554) 7. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE. Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012
  8. (PMID: 22502709) [CrossRef] 8. Wintrob ZA, Hammel JP, Khoury T, Nimako GK, Fu HW, Fayazi ZS, Gaile DP, Forrest A, Ceacareanu AC. Insulin use, adipokine profiles and breast cancer prognosis. Cytokine 2017
  9. (PMID: 27914795) [CrossRef] 9. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in earlystage breast cancer: Results of a prospective cohort study. J Clin Oncol 2002
  10. (PMID: 11773152) [CrossRef] 10. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006
  11. (PMID: 16450399) [CrossRef] 11. Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/ IGF receptors are major regulators of breast cancer cells. Breast Dis 2003
  12. (PMID: 15687679) [CrossRef] 12. Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Bharadwaj M, Tandon N, Bharadwaj D. High-sensitivity C-reactive protein levels and type 2 diabetes in urban